User profiles for "author:Antoni Ribas"

Antoni Ribas

UCLA
Verified email at mednet.ucla.edu
Cited by 164680

Cancer immunotherapy using checkpoint blockade

A Ribas, JD Wolchok - Science, 2018 - science.org
The release of negative regulators of immune activation (immune checkpoints) that limit
antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in …

[HTML][HTML] Primary, adaptive, and acquired resistance to cancer immunotherapy

P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas - Cell, 2017 - cell.com
Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Classifying cancers based on T-cell infiltration and PD-L1

MWL Teng, SF Ngiow, A Ribas, MJ Smyth - Cancer research, 2015 - AACR
Cancer immunotherapy may become a major treatment backbone in many cancers over the
next decade. There are numerous immune cell types found in cancers and many …

[HTML][HTML] Improved survival with vemurafenib in melanoma with BRAF V600E mutation

PB Chapman, A Hauschild, C Robert… - … England Journal of …, 2011 - Mass Medical Soc
Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib
(PLX4032) have shown response rates of more than 50% in patients with metastatic …

PD-1 blockade induces responses by inhibiting adaptive immune resistance

PC Tumeh, CL Harview, JH Yearley, IP Shintaku… - Nature, 2014 - nature.com
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types,,,,. One mechanism …

[HTML][HTML] Pembrolizumab versus ipilimumab in advanced melanoma

C Robert, J Schachter, GV Long… - … England Journal of …, 2015 - Mass Medical Soc
Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 …

[HTML][HTML] Genetic basis for clinical response to CTLA-4 blockade in melanoma

A Snyder, V Makarov, T Merghoub… - … England Journal of …, 2014 - Mass Medical Soc
Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …

[HTML][HTML] Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma

O Hamid, C Robert, A Daud, FS Hodi… - … England Journal of …, 2013 - Mass Medical Soc
Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …

[HTML][HTML] Inhibition of mutated, activated BRAF in metastatic melanoma

KT Flaherty, I Puzanov, KB Kim, A Ribas… - … England Journal of …, 2010 - Mass Medical Soc
Background The identification of somatic mutations in the gene encoding the serine–
threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to …

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

ME Davis, JE Zuckerman, CHJ Choi, D Seligson… - Nature, 2010 - nature.com
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the
potential to provide new, major ways of imparting therapy to patients,. Long, double …